Drug Resistance in Epilepsy

The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.

• Chair's Introduction (V. Ling). The problem of the drug-resistant epilepsies (J. W. Sander). Drug resistance molecules: lessons from oncology (George L.Scheffer and Rik J. Scheper). Drug resistance in epilepsy: the role of the blood-brain barrier(N. Joan Abbott, et al.). P glycoprotein and the mechanism of multidrug resistance (A.Varadi, et al). Drug resistance caused by multidrug resistance-associated proteins(J. Wijnholds). Reversal of multidrug resistance: lessons from clinical oncology(S. E. Bates, et al.). Clinical development of P glycoprotein modulators in oncology (A.Oza). Gene expression profiling of epothilone A-resistant cells (P.Atadja, et al.). Imaging of P glycoprotein function in vivo with PET (N. H.Hendrikse and W. Vaalburg). Animal models of drug-resistant epilepsy (W. Loscher). Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, etal). Cellular mechanisms of pharmacoresistance in slices from epilepsysurgery (R. A. Deisz). Functional polymorphisms of the human multidrug resistance (MDR1)gene: correlation with P glycoprotein expression and activity invivo (U. Brinkmann). OC144-093, a novel P glycoprotein inhibitor for the enhancement ofanti-epileptic therapy (M. J. Newman, et al.). Closing remarks (V. Ling). Index of contributors. Subject Index.